GROUP SALES grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%....
APPROVAL BASED ON PHASE III ALINA STUDY SHOWING ALECENSA REDUCED THE RISK OF DISEASE RECURRENCE OR DEATH BY AN UNPRECEDENTED 76% IN PEOPLE WITH ALK-POSITIVE EARLY-STAGE RESECTED NON-SMALL CELL L...
RESULTS FROM THE PHASE III STUDY SHOWED THAT SUBCUTANEOUS (SC) INJECTION WAS CONSISTENT WITH IV INFUSION AND DEMONSTRATED NEAR-COMPLETE SUPPRESSION OF RELAPSE ACTIVITY (97%) AND MRI LESIONS (97....
COLUMVI, IN COMBINATION WITH CHEMOTHERAPY, DEMONSTRATED A STATISTICALLY SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL FOR PEOPLE WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA DATA FROM...
THE ELECSYS® PTAU217 PLASMA BIOMARKER TEST IS BEING DEVELOPED AS PART OF AN ONGOING PARTNERSHIP BETWEEN ROCHE AND ELI LILLY AND COMPANY ONCE APPROVED, THE TEST WILL AID HEALTHCARE PROVIDERS IN ...
THE COBAS MALARIA TEST IS THE FIRST FDA-APPROVED MOLECULAR TEST TO SCREEN U.S. BLOOD DONORS FOR MALARIA MALARIA IS A SERIOUS AND POTENTIALLY FATAL PARASITIC INFECTION MOST COMMONLY TRANSMITTED B...
ALL PROPOSALS OF THE BOARD OF DIRECTORS APPROVED SEVERIN SCHWAN RE-ELECTED AS CHAIRMAN OF THE BOARD OF DIRECTORS; ALL OTHER BOARD MEMBERS STANDING FOR ELECTION CONFIRMED 37TH CONSECUTIVE DIVIDEN...
KARDIA-2 STUDY MET ITS PRIMARY ENDPOINT, DEMONSTRATING CLINICALLY SIGNIFICANT SYSTOLIC BLOOD PRESSURE REDUCTIONS IN EACH TREATMENT ARM AT MONTH THREE ZILEBESIRAN ADDED TO A STANDARD OF CARE HYPE...
DETAILED RESULTS FROM THE NIH-SPONSORED PHASE III OUTMATCH STUDY SHOWED TREATMENT WITH XOLAIR INCREASED THE AMOUNT OF PEANUTS, TREE NUTS, EGG, MILK AND WHEAT THAT PEOPLE AS YOUNG AS 1 YEAR CONSU...
APPROVAL IS BASED ON DATA FROM THE NIH-SPONSORED PHASE III OUTMATCH STUDY, WHICH SHOWED A SIGNIFICANTLY HIGHER PROPORTION OF FOOD ALLERGY PATIENTS AS YOUNG AS 1 YEAR TREATED WITH XOLAIR COULD TO...